Overview
BioSerenity Group, four times winner of the French Tech Next40/120 programme, has since its creation been working on improving access to diagnosis and management of chronic diseases (cardiology, neurology and sleep disorders).
Its takeover was realized through a disposal plan, which was approved by the Paris Commercial Court on November 10, 2023. Through this sale plan, BioSerenity Group has ensured the continuation of its three activities: production of connected medical devices, development of software interpreting data using AI engines, and performance of diagnostic procedures.
The French venture capital fund Jolt Capital, which was chosen after a competitive process, has already announced a €24 million investment to accelerate the company’s international development and the deployment of its innovative solutions.
The McDermott team advising BioSerenity Group comprised:
- Timothée Gagnepain, partner, Théophile Jomier, counsel, Rudi Pfortner, associate, on the restructuring aspects
- Anne-France Moreau, partner, on the regulatory/life sciences aspects.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
